167 related articles for article (PubMed ID: 33189726)
1. Development of magnetic particle-based chemiluminescence immunoassay for measurement of human procalcitonin in serum.
Liao M; Zheng J; Xu Y; Qiu Y; Xia C; Zhong Z; Liu L; Liu H; Liu R; Liang S
J Immunol Methods; 2021 Jan; 488():112913. PubMed ID: 33189726
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel chemiluminescence immunoassay for the detection of procalcitonin.
Wang G; Wan Y; Lin G; Li Z; Dong Z; Liu T
J Immunol Methods; 2020; 484-485():112829. PubMed ID: 32673618
[TBL] [Abstract][Full Text] [Related]
3. Magnetic particle-based chemiluminescence immunoassay for serum human heart-type fatty acid binding protein measurement.
Zheng J; Qiu Y; Xu Y; Quan M; Zhong Z; Wang Q; Wu Y; Zeng X; Xia C; Liu R
Biotechnol Lett; 2023 Dec; 45(11-12):1431-1440. PubMed ID: 37736778
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Abbott Architect BRAHMS and the Biomérieux Vidas BRAHMS Procalcitonin Assays.
Wang D; Caddell B; Nolte FS; Babic N
J Appl Lab Med; 2019 Jan; 3(4):580-586. PubMed ID: 31639727
[TBL] [Abstract][Full Text] [Related]
5. A new strategy for the development of monoclonal antibodies for the determination of human procalcitonin in serum samples.
Kremmer E; Meyer K; Grässer FA; Flatley A; Kösters M; Luppa PB; Krämer PM
Anal Bioanal Chem; 2012 Jan; 402(2):989-95. PubMed ID: 22006244
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay.
Hubl W; Krassler J; Zingler C; Pertschy A; Hentschel J; Gerhards-Reich C; Mack M; Demant T
Clin Lab; 2003; 49(7-8):319-27. PubMed ID: 12908732
[TBL] [Abstract][Full Text] [Related]
7. Development of a fluorescent immnunochromatographic assay for the procalcitonin detection of clinical patients in China.
Wang H; Wang H; Chen S; Dzakah EE; Kang K; Wang J; Wang J
Clin Chim Acta; 2015 Apr; 444():37-42. PubMed ID: 25659293
[TBL] [Abstract][Full Text] [Related]
8. Analytical evaluation of Lumipulse® BRAHMS PCT CLEIA assay and clinical performances in an unselected population as compared with central lab PCT assay.
Dupuy AM; Né M; Bargnoux AS; Badiou S; Cristol JP
Clin Biochem; 2017 Mar; 50(4-5):248-250. PubMed ID: 27838408
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel homogeneous nanoparticle-based assay for sensitive procalcitonin detection of ultra low-volume serum samples.
Li P; Chen Z; Liu B; Li K; Wang H; Lin L; He L; Wei J; Liu T
Int J Nanomedicine; 2018; 13():5395-5404. PubMed ID: 30254442
[TBL] [Abstract][Full Text] [Related]
10. Development of magnetic particle-based chemiluminescence immunoassay for measurement of SARS-CoV-2 nucleocapsid protein.
Xu Y; Xia C; Zeng X; Qiu Y; Liao M; Jiang Q; Quan M; Liu R
J Virol Methods; 2022 Apr; 302():114486. PubMed ID: 35108595
[TBL] [Abstract][Full Text] [Related]
11. A semi-quantitative rapid multi-range gradient lateral flow immunoassay for procalcitonin.
Serebrennikova KV; Samsonova JV; Osipov AP
Mikrochim Acta; 2019 Jun; 186(7):423. PubMed ID: 31187212
[TBL] [Abstract][Full Text] [Related]
12. Determining the concentration of procalcitonin using a magnetic particles-based chemiluminescence assay for the clinical diagnosis of sepsis.
Qi S; Li Q; Rao W; Liu X; Yin L; Zhang H
Anal Sci; 2013; 29(8):805-10. PubMed ID: 23934561
[TBL] [Abstract][Full Text] [Related]
13. Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay.
Ruzzenente O; Salvagno GL; Gelati M; Lippi G
Pract Lab Med; 2016 Dec; 6():8-13. PubMed ID: 28856208
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of procalcitonin immunoassay concordance near clinical decision points.
Chambliss AB; Hayden J; Colby JM
Clin Chem Lab Med; 2019 Aug; 57(9):1414-1421. PubMed ID: 30763263
[TBL] [Abstract][Full Text] [Related]
15. Analytical evaluation of the novel VITROS BRAHMS procalcitonin immunoassay.
Dupuy AM; Bargnoux AS; Montagnon V; Kuster N; Badiou S; Cristol JP
Scand J Clin Lab Invest; 2020 Nov; 80(7):541-545. PubMed ID: 33124916
[TBL] [Abstract][Full Text] [Related]
16. As a Novel Procalcitonin Assay is Architect B∙R∙A∙H∙M∙S PCT; Comparison of Two Commercial Systems.
Aydemir Ö; Karakeçe E; Köroğlu M; Aydemir Y; Terzi HA; Erkorkmaz Ü; Altindiş M
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969065
[TBL] [Abstract][Full Text] [Related]
17. Two-center comparison of 10 fully-automated commercial procalcitonin (PCT) immunoassays.
Lippi G; Salvagno GL; Gelati M; Pucci M; Lo Cascio C; Demonte D; Faggian D; Plebani M
Clin Chem Lab Med; 2019 Dec; 58(1):77-84. PubMed ID: 31539351
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis of bacterial infection using procalcitonin].
Takajo I; Okayama A
Rinsho Byori; 2010 May; 58(5):517-22. PubMed ID: 20560461
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of new rat monoclonal antibodies for procalcitonin.
Krämer PM; Gouzy MF; Kess M; Kleinschmidt U; Kremmer E
Anal Bioanal Chem; 2008 Oct; 392(4):727-36. PubMed ID: 18712365
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Procalcitonin Assay on the Abbott Architect i1000.
Pagaduan JV; Tam E; Devaraj S
J Appl Lab Med; 2019 May; 3(6):936-942. PubMed ID: 31639685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
